Suboxone withdrawal severity, duration, and management depend on the buprenorphine dose history that precedes it, the medication-assisted treatment used to ease it, and whether you taper under medical supervision or stop abruptly. Understanding the withdrawal timeline and your safe treatment options matters for both your physical safety and your relapse risk.
This guide covers what causes Suboxone withdrawal, what to expect across the first month, medical management for opioid dependence, modern slow-taper protocols, inpatient versus outpatient choices, and aftercare that supports recovery from opioid addiction.
It is written for adults in the Denver metro area and Broomfield, Colorado who are evaluating medically supervised detox and ongoing care.
Key Takeaways
- Onset is 24–72 hours after the last dose: Buprenorphine’s long half-life (24–42 hours) means symptoms emerge slowly, peak around day 3, and last 7–14 days for the acute phase.
- PAWS can extend symptoms for weeks to months: Post-acute withdrawal syndrome (mood instability, sleep disturbance, anhedonia, cravings) is one of the strongest drivers of relapse without ongoing care.
- Slow tapers are now standard: 2024–2026 clinical guidance favors gradual dose reductions over abrupt stops, often using fractional film dosing or long-acting injectable buprenorphine as a built-in taper.
- Medicaid covers detox and residential care in Colorado: Many adults assume cost is a barrier when their plan already covers a stay, verifying coverage is the fastest first step.
If you’re navigating a Suboxone taper or withdrawal, our medically supervised detox in Broomfield provides 24/7 clinical oversight for adults stabilizing on or off buprenorphine.
Call 720-807-7867 to verify insurance and discuss next steps.
What Suboxone withdrawal is and why it happens
Suboxone is the brand name for a combination of buprenorphine and naloxone, a long-acting partial agonist at the mu opioid receptor used in medication-assisted treatment for opioid use disorder and, in some cases, opioid pain conditions.
It is a Schedule III controlled substance and one of the most widely used forms of opioid replacement therapy and medication-assisted therapy in the United States. Withdrawal is the set of physical and psychological symptoms that can appear when you reduce or stop it.
At Foundry Front Range, we provide 24/7 clinical oversight for adults navigating buprenorphine withdrawal in Broomfield, Colorado. Our team can help stabilize symptoms and coordinate the next step in care.
How buprenorphine works at the receptor
Buprenorphine binds tightly to mu opioid receptors but only partially activates them. This produces a “ceiling effect,” past a moderate dose, additional buprenorphine produces little extra opioid effect, which lowers overdose risk while still suppressing cravings.
Because the binding affinity is high, buprenorphine can displace full agonists like heroin, oxycodone, or fentanyl from those same receptors. That displacement is the mechanism behind precipitated withdrawal during induction. When dosing stops, net receptor activation falls and a body that adapted to partial stimulation signals discomfort.
Dependence is not the same as addiction
Physical dependence means your body has adapted to the medication and you experience withdrawal if it is stopped. Addiction involves compulsive use despite harm. Many people on Suboxone are physically dependent without being addicted to it, which is why the framing of “tapering off” is clinically different from “treating addiction.”
This distinction matters because it changes the plan. A taper schedule, continued maintenance, or a transition to naltrexone are all reasonable options depending on your history and goals.
Precipitated withdrawal during induction
Precipitated withdrawal happens when buprenorphine is started while a full agonist is still active at the receptors. The displacement causes a sudden drop in receptor activation and severe withdrawal symptoms appear within minutes.
Careful timing, guided by the Clinical Opiate Withdrawal Scale (COWS), and updated low-dose initiation protocols reduce this risk, especially for people coming off fentanyl. We cover modern induction strategies in the medical management section below.
Suboxone Withdrawal Symptoms Timeline: Simple Chart
The Suboxone withdrawal timeline typically begins 24 to 72 hours after the last dose, peaks around day 3, and eases over 1 to 2 weeks for the acute phase. A protracted phase known as post-acute withdrawal syndrome (PAWS) can persist for weeks to months in some people.
| Timeframe | What you may experience | Typical severity |
| 0–24 hours | Restlessness, mild anxiety, yawning, increased sweating | Mild |
| 24–72 hours | Muscle aches, GI upset, insomnia, chills, dilated pupils, peak cravings | Moderate to severe |
| Days 4–7 | Symptoms begin to ease; fatigue, low mood, poor sleep persist | Moderate |
| Weeks 2–4 | Most physical symptoms resolve; mood, sleep, energy still uneven | Mild to moderate |
| 1 month and beyond (PAWS) | Cravings, anhedonia, mood instability, cognitive fog, sleep disturbance | Variable; often episodic |
Physical withdrawal symptoms
The acute phase brings restlessness, muscle aches, yawning, sweating with hot flashes and chills, runny nose, dilated pupils, and gastrointestinal detox symptoms including nausea, vomiting, and diarrhea. Sleep is often disrupted for the first 7–10 days.
These symptoms are uncomfortable but rarely life-threatening on their own. Risk rises with co-occurring benzodiazepine, alcohol, or stimulant use, and with underlying medical conditions like cardiac disease.
Psychological aspects of withdrawal
Anxiety, low mood, irritability, and intense cravings often outlast the physical symptoms. Many people describe the emotional weight of withdrawal, the dread, the boredom, the loss of routine, as harder than the body symptoms.
This is part of why aftercare planning before detox starts matters. Therapy, peer support, and continued medical follow-up address the part of withdrawal that does not resolve in 7 days.
PAWS: post-acute withdrawal syndrome
PAWS is a recognized post-acute phase that can follow opioid withdrawal of any kind, including from buprenorphine. Symptoms include episodic cravings, sleep disturbance, anhedonia (reduced ability to feel pleasure), cognitive fog, and mood instability. It can persist for weeks to several months.
PAWS is one of the strongest drivers of relapse in the months after detox. Naming it, expecting it, and planning for ongoing therapy and peer support gives people a much better chance of staying off opioids during this fragile window.
How duration of use changes the timeline
Short-term Suboxone use (under 30 days) typically produces a milder, shorter acute withdrawal, often 5–7 days. Long-term use (months to years), higher doses, and prior methadone exposure tend to extend both the acute phase and the likelihood of PAWS.
These individual factors, along with metabolism, age, and co-occurring conditions, make any timeline an estimate rather than a guarantee.
What increases or decreases withdrawal severity
Suboxone withdrawal varies meaningfully from person to person. Higher buprenorphine exposure over time, prior methadone use, untreated medical or psychiatric conditions, and abrupt discontinuation all tend to make it worse. Slow tapering managed by medical professionals, ongoing oversight, and continuity of care reduce severity and the relapse-driven risk of overdose deaths from reduced tolerance.
| Factor | Effect on withdrawal | Why it matters clinically |
| Higher daily dose / longer use | Longer, more intense withdrawal | More receptor adaptation to reverse |
| Prior methadone exposure | Often extends timeline | Methadone has a longer half-life than buprenorphine |
| Abrupt stop vs. taper | Abrupt = more severe | Slow reductions allow gradual re-equilibration |
| Co-occurring benzodiazepine or alcohol use | Higher medical risk | Withdrawal stacking, possible seizure risk |
| Pregnancy | Specialized management required | Untreated withdrawal can affect fetal outcomes |
| Untreated anxiety or depression | Symptoms feel worse, relapse risk higher | Underlying conditions amplify discomfort |
| Older age, liver disease | Slower metabolism, longer course | Pharmacokinetics shift |
| Access to MOUD and supervised care | Reduces severity and complications | Continuity of care is protective |
Compare service options on our drug and alcohol detox program page if you are weighing detox alongside immediate residential support. Timely, medically supervised care reduces risk and supports a smoother transition into longer-term treatment.
Medical management: Buprenorphine, methadone, alpha-2 agonists, and supportive care
Three medication categories are used to manage Suboxone withdrawal: continued or restarted buprenorphine, methadone, and alpha-2 agonists like clonidine and lofexidine hydrochloride. Comfort medications and a careful naltrexone bridge round out the toolkit.
Choice depends on access, clinical risk, and the care setting. Our residential addiction treatment program coordinates medical management with integrated mental health care for adults in the Denver metro area.
Buprenorphine induction and dosing
For people who are tapering off Suboxone but need to re-stabilize, buprenorphine itself is often the safest tool. Standard induction begins when the Clinical Opiate Withdrawal Scale indicates moderate withdrawal, typically a COWS score of 8 or higher, to avoid precipitated withdrawal.
Sublingual induction commonly starts at 2–4 mg, with titration toward 8–16 mg daily based on symptom control. A test dose followed by 60–120 minutes of observation is the standard safety check before a full dose.
Methadone
Methadone is a full opioid agonist, like the analgesic opioids it can replace, that often provides steadier suppression of withdrawal than buprenorphine. It is dispensed only through licensed opioid treatment programs, requires daily supervised dosing during titration, and may suit people whose withdrawal is severe or whose buprenorphine response has been inadequate.
Initial methadone dosing is typically 10–30 mg under clinic supervision, adjusted carefully for symptom control and respiratory safety.
Clonidine and lofexidine
Alpha-2 agonists target the autonomic symptoms of withdrawal, sweating, hypertension, anxiety, GI distress. Clonidine is widely available and inexpensive but can cause significant low blood pressure and requires monitoring.
Lofexidine is FDA-approved specifically for opioid withdrawal symptoms and tends to cause less hypotension than clonidine. Either is an adjunct, not a replacement for buprenorphine or methadone when those are clinically appropriate.
Comfort medications and the naltrexone bridge
Comfort medications target specific symptoms alongside primary withdrawal management. Antiemetics like ondansetron, NSAIDs or acetaminophen for muscle pain, loperamide for diarrhea, and short-term sleep aids are common adjuncts. Sedating medications should be used cautiously, additive effects with alcohol or benzodiazepines raise respiratory depression risk.
Transitioning to extended-release naltrexone requires a true opioid-free interval, typically 7–14 days after the last buprenorphine dose, confirmed by clinical assessment. Starting naltrexone too early precipitates severe withdrawal.
Modern tapering strategy: slow reductions, fractional films, and the long-acting injectable off-ramp
Clinical practice has shifted in 2024–2026 toward gradual buprenorphine tapers, fractional film dosing, and the use of long-acting injectable buprenorphine as a tapering tool.
The older approach of stopping buprenorphine over a few weeks has largely been replaced by slower, individualized treatment plans for medical tapering, off-ramps that better match the medication’s pharmacology and reduce withdrawal severity.
Why slow tapers replaced abrupt discontinuation
Buprenorphine has a long half-life and unusually slow receptor dissociation. Abrupt stops, even from low doses, often produce a delayed and prolonged withdrawal that drives people back to opioid use. Gradual reductions allow your nervous system to re-equilibrate at each dose level before another step down.
This shift aligns with our evidence-based, whole-patient treatment philosophy, matching the pace of care to the biology of recovery rather than the convenience of a calendar.
Sample dose-reduction schedules
There is no single right tapering schedule. A common framework reduces the daily dose by about 25% every 2–4 weeks, holding longer at low doses.
For someone on 16 mg daily, that might look like 12 mg → 8 mg → 6 mg → 4 mg → 2 mg → 1 mg → 0.5 mg, with each level held for 2–4 weeks and longer at the bottom.
Symptom severity at each step guides whether to advance, hold, or reverse on the tapering plan. The goal of any plan built with an addiction specialist is a tolerable transition, not a fast one.
Fractional film dosing for low-dose tapers
Below 2 mg, the difference between dose levels matters more and standard films become difficult to divide cleanly. Cutting a 2 mg film into halves or quarters, or pharmacist-compounded liquid buprenorphine, allows reductions of 0.25 mg or smaller.
This precision is where many tapers succeed or fail. Going from 2 mg to 0 in one step is a large pharmacologic jump and typically produces a worse withdrawal than dropping to 1 mg, then 0.5 mg, then off.
Long-acting injectable buprenorphine as a tapering tool
Sublocade and Brixadi are extended-release buprenorphine injections originally developed for OUD maintenance. Because plasma levels decline gradually after the last injection, over months rather than days, these formulations can function as a built-in slow taper.
A common pathway is to stabilize on monthly injections, then either lower the injection dose or stop injections and let plasma levels fall naturally over the following months.
This approach removes the need for daily decisions about whether to reduce a film and smooths the off-ramp pharmacokinetically. As with any clinical decision, it should be made with a prescribing clinician familiar with depot buprenorphine.
Fentanyl-era considerations
Many adults seeking to taper Suboxone in 2025–2026 originally entered treatment after fentanyl use. Fentanyl is highly lipophilic, accumulates in fatty tissue, and releases slowly back into circulation, which means precipitated withdrawal during initial buprenorphine induction is more likely than it was with heroin or prescription opioids.
This same persistence affects tapering decisions later. People with significant fentanyl exposure history often benefit from slower tapers, longer holds at each dose level, and lower-threshold access to medical reassessment if symptoms intensify.
Inpatient versus outpatient detox: matching level of care to clinical risk
The choice between medically supervised inpatient detox and outpatient management is a clinical one, driven by an evaluation and assessment of medical and psychiatric risk, polysubstance use, social supports, and recent overdose or suicidality. ASAM Level 3.7 medically monitored withdrawal management provides 24/7 nursing and medical oversight when those risk factors are present.
To verify whether our medically supervised detox is appropriate for your situation, contact our admissions team anytime.
When inpatient detox is the safer choice
Our ASAM 3.7 medically monitored detox is appropriate when one or more of the following apply: co-occurring benzodiazepine or alcohol use, pregnancy, recent overdose, active suicidal ideation, unstable medical conditions (cardiac, respiratory, hepatic), prior failed outpatient tapers, severe co-occurring mental health symptoms, or unsafe home environment.
In those situations, 24/7 nursing observation, medical monitoring, and integrated psychiatric care meaningfully reduce the risk of complications and improve the chance of completing detox. Residential inpatient treatment that follows the detox phase extends this clinical support into a longer therapeutic treatment plan.
When outpatient management can work
For lower-risk adults with stable supports, intact housing, no significant polysubstance use, and a prescribing clinician who can adjust the taper week to week, outpatient management is often appropriate. Continuing to work, parent, or attend school during a slow taper is realistic for many people.
A planned step-down to our intensive outpatient program after the most intense weeks can bridge the gap between residential care and ordinary life.
Emergency criteria
Seek emergency medical care immediately for unstable vital signs, seizures, respiratory depression, severe dehydration unresponsive to home management, chest pain, or active suicidal ideation with intent or plan. Withdrawal alone is rarely fatal, but co-occurring conditions and complications can be.
Pregnancy and special populations
Pregnant patients should be managed in coordination with obstetric and addiction medicine specialists. Untreated withdrawal in pregnancy carries fetal risk, and medication choices, dosing, and monitoring all change. People with severe psychiatric comorbidity, pediatric patients, and people transitioning out of incarceration generally need a higher level of care and structured handoffs.
Coping strategies, non-pharmacologic supports, and aftercare
Medications stabilize the body; the rest of the recovery process happens through therapy, peer support, structure, and time. Strong support systems and holistic care meaningfully reduce relapse risk in the months after withdrawal, the window when PAWS and unprocessed life stress drive most returns to use.
For people leaving detox or residential care, our family addiction support program helps loved ones become recovery advocates without absorbing the work themselves.
Evidence-based therapies and behavioral supports
Cognitive behavioral therapy, delivered by substance abuse counselors or licensed clinicians, helps reframe triggers and build coping skills for cravings and PAWS symptoms. According to the National Institute on Drug Abuse review of medications for opioid use disorder, the strongest outcomes come from combining MOUD with evidence-based therapies rather than either alone.
Contingency management, small, structured rewards for verified abstinence, has decades of evidence behind it for stimulant and opioid use disorders. Supportive therapy, peer support through 12-Step meetings or SMART Recovery groups, and structured support groups add accountability and community as recovery tools for the months after detox.
Naloxone and overdose prevention
Anyone tapering Suboxone or transitioning between medications should carry naloxone. Tolerance drops quickly during a taper, which means the dose of opioids that was tolerated before could now cause a fatal overdose if relapse occurs.
Naloxone is available without a prescription at Colorado pharmacies and is covered by most insurance, including Medicaid. Friends, family, and roommates should know where it is and how to use it.
Managing PAWS symptoms
Antidepressants, sleep medications, or non-stimulant ADHD treatments can be considered for persistent PAWS symptoms after psychiatric assessment. Sleep hygiene, regular exercise (even light walking), structured meals, and limiting alcohol all support the nervous system through the protracted phase.
Refer to psychiatry if symptoms impair daily functioning or raise safety concerns. PAWS is treatable, not just something to wait out.
Aftercare checklist
Before completing detox, the following should be in place: a current medication reconciliation list, a naloxone kit, 24/7 contact numbers for the prescribing clinician and a trusted support person, a scheduled follow-up appointment, a referral to outpatient therapy or IOP, and a peer-support schedule for the first 30 days.
Medicaid coverage and finding medically supervised detox in Broomfield and Denver
Medicaid covers medical detox programs and residential addiction treatment in Colorado, including ASAM 3.7 and 3.5 levels of care. Many adults assume cost is the barrier when their plan would already cover a stay, verifying coverage is the fastest first step.
Foundry Front Range accepts Medicaid for both detox and residential care. You can review our Medicaid-covered rehab options or verify your insurance benefits before arrival.
What to look for in a detox program
Programs should clearly state ASAM level (3.7 for medically monitored detox, 3.5 for residential), licensed medical director, 24/7 nursing, and the ability to initiate or continue MOUD on site. Look for an addiction specialist on staff and case management services that coordinate insurance, housing, and aftercare.
Warm handoffs into residential or outpatient care matter as much as the detox itself. Individualized case management, a stabilized patient discharged into a clear next step, is what separates programs that hold gains from ones that lose them.
Why facility features matter
On-site medical staff, integrated co-occurring mental health treatment, and continuity from detox into residential or outpatient care reduce the risk of unmanaged symptoms, untreated psychiatric conditions, and overdose. Our 44,000-square-foot Broomfield facility houses both ASAM 3.7 detox and ASAM 3.5 residential treatment under one roof, with Joint Commission accreditation.
What to bring for Medicaid intake
Bring your current Medicaid ID, a photo ID, recent proof of income or household if available, and any prior authorization or behavioral-health referral you already have. Calling your Medicaid plan ahead of arrival to confirm coverage rules and any prior authorization requirements can prevent delays in admission.
Get a confidential clinical assessment
If you or a loved one are planning a Suboxone taper or facing withdrawal, our admissions team can help you verify insurance, discuss medically supervised detox, and determine whether Foundry Front Range is appropriate for your situation. A brief intake conversation reviews your history, assesses withdrawal risk, and helps map out a safer next step.
Begin the admissions process at Foundry Front Range or call 720-807-7867 to speak with our team today.
Suboxone Withdrawal FAQ
Here are some questions people also ask about suboxone tithdrawal timeline and symptoms, and subtance use disorders more generally.
What COWS score is used to start buprenorphine, and how does that prevent precipitated withdrawal?
A Clinical Opiate Withdrawal Scale score of 8 or higher is the practical threshold most protocols use before giving the first buprenorphine dose. That score corresponds to clinically observable symptoms: yawning, lacrimation, dilated pupils, sweating, runny nose, GI upset, that indicate enough spontaneous withdrawal for buprenorphine to bind without displacing residual full agonists.
In practice, the clinician confirms objective signs, gives a 2–4 mg test dose, observes for 60–90 minutes, then continues titration if tolerated. If precipitated withdrawal occurs anyway, supportive care, additional buprenorphine in experienced hands, or transfer to a higher level of care are options depending on severity.
Can buprenorphine be used to bridge to naltrexone?
Yes, but the timing is the whole game. Naltrexone is an opioid antagonist and will precipitate severe withdrawal if it is started while opioids still occupy the receptors.
A typical approach tapers buprenorphine to a low dose, stops it, and waits 7–14 days, confirmed by low COWS and clinical assessment, before initiating naltrexone.
Some specialized rapid-transition protocols use lower-threshold approaches under close monitoring, but these are program-specific. Many people do better staying on buprenorphine for maintenance rather than switching to naltrexone, given the lower overdose and relapse rates that maintenance therapy provides.
How does lofexidine compare to buprenorphine for community detox?
Lofexidine is FDA-approved for opioid withdrawal symptoms and reduces autonomic symptoms (sweating, hypertension, anxiety), but it does not address cravings the way buprenorphine does. Trial data show lofexidine eases short-course detox but generally produces lower retention and higher rates of return to opioid use than buprenorphine maintenance.
Lofexidine is reasonable when agonist therapy is not desired or available. Buprenorphine is generally preferred when the clinical goal is retention and relapse prevention.
Are depot or single high-dose buprenorphine formulations effective for detox?
Long-acting injectable buprenorphine (Sublocade, Brixadi) has been studied primarily for treatment retention and reduces illicit opioid use in many trials. These formulations are most often used for maintenance, but the slow plasma decline after the last injection can also serve as a built-in taper.
Single high-dose depot approaches for short detox are less well established and are used only within specialized clinical protocols. Discuss long-acting options with a prescribing clinician familiar with their pharmacology.
What ancillary medications help with Suboxone withdrawal symptoms?
Common symptomatic medications include ondansetron or promethazine for nausea, NSAIDs or acetaminophen for muscle pain, loperamide for diarrhea, and short courses of trazodone or sedating antihistamines for sleep. Clonidine and lofexidine help with autonomic symptoms.
Watch for additive sedation if combining with alcohol or benzodiazepines. Clonidine and lofexidine require blood pressure monitoring, and NSAIDs should be used cautiously with renal disease or GI bleeding risk.
A clinician familiar with your medical history should choose and monitor the combination.
Is Suboxone withdrawal dangerous on its own?
Acute Suboxone withdrawal is rarely fatal in adults without complicating conditions. Risk rises with co-occurring benzodiazepine or alcohol use, pregnancy, recent overdose, severe dehydration, cardiac disease, or active suicidality.
When any of those apply, medically supervised detox is the safer choice. The bigger long-term risk is relapse, and the dramatically increased overdose risk that comes with reduced tolerance.
